Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C

Fang,Fuxiao; Yuan,Qing

doi:10.3892/ol.2021.13164

Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C

Authors:
- Fuxiao Fang
- Qing Yuan
View Affiliations

Affiliations: Operating Room, Deqing County People's Hospital, Huzhou, Zhejiang 313200, P.R. China, Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: December 13, 2021 https://doi.org/10.3892/ol.2021.13164
Article Number: 46
Copyright: © Fang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The vascular endothelial growth factor receptor (VEGFR) network contributes to breast cancer pathogenesis and progression. Anlotinib is a highly potent multi‑target tyrosine kinase inhibitor that has been previously shown to exert antitumor effects in various types of cancer. The aim of the present study is to investigate the effect of Anlotinib against breast cancer cells in vitro and uncover the possible underlying mechanisms. The human breast cancer cell line MCF‑7 was treated with different concentrations of Anlotinib, before cell proliferation, migration, invasion and apoptosis were assessed using colony formation, wound healing, Transwell and TUNEL staining assays. In addition, the expression of transcription factor AP‑2γ (TFAP2C) following Anlotinib stimulation was measured using reverse transcription‑quantitative PCR and western blot analysis. TFAP2C was overexpressed in MCF‑7 using transfection with a pcDNA3.1 vector, before the aforementioned experiments were repeated. The results revealed that Anlotinib impaired cell viability and colony formation, reduced proliferating cell nuclear antigen, Ki‑67, MMP2, MMP9 and Bcl‑2 expression levels, and inhibited cell migration and invasion. By contrast, the expression levels of tissue inhibitor of metalloproteinase 1, the frequency of apoptotic cells, the expression of Bax and the cleaved caspase‑3/caspase‑3 ratio increased in a concentration‑dependent manner. Additionally, the expression of TFAP2C decreased after Anlotinib treatment. However, TFAP2C overexpression partially blocked the effects of Anlotinib on the proliferation, migration, invasion and apoptosis of MCF‑7 cells. To conclude, Anlotinib suppressed proliferation, migration and invasion, whilst inducing apoptosis of MCF‑7 cells, which may be partially dependent on the inhibition of TFAP2C expression.

View Figures

View References

1	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
2	Tajima T, Tokuda T and Kubota M: Treatment of advanced breast cancer: current issues. Cancer and Chemotherapy. 25:1832–1840. 1998.(In Japanese). PubMed/NCBI
3	Maughan KL, Lutterbie MA and Ham PS: Treatment of breast cancer. Am Fam Physician. 81:1339–1346. 2010.PubMed/NCBI
4	Yang J, Yan J and Liu B: Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 9:9782018. View Article : Google Scholar : PubMed/NCBI
5	Jiao Q, Bi L, Ren Y, Song S, Wang Q and Wang YS: Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 17:362018. View Article : Google Scholar : PubMed/NCBI
6	Kerbel RS: Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia. 17:229–239. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gao Y, Liu P and Shi R: Anlotinib as a molecular targeted therapy for tumors. Oncol Lett. 20:1001–1014. 2020. View Article : Google Scholar : PubMed/NCBI
8	Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, et al: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 9:1052016. View Article : Google Scholar : PubMed/NCBI
9	Syed YY: Anlotinib: First global approval. Drugs. 78:1057–1062. 2018. View Article : Google Scholar : PubMed/NCBI
10	Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 4:1569–1575. 2018. View Article : Google Scholar : PubMed/NCBI
11	Li L, Yu J, Jiao S, Wang W, Zhang F and Sun S: Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells. OncoTargets Ther. 11:8543–8553. 2018. View Article : Google Scholar : PubMed/NCBI
12	De Andrade JP, Park JM, Gu VW, Woodfield GW, Kulak MV, Lorenzen AW, Wu VT, Van Dorin SE, Spanheimer PM and Weigel RJ: EGFR is regulated by TFAP2C in luminal breast cancer and is a target for vandetanib. Mol Cancer Ther. 15:503–511. 2016. View Article : Google Scholar : PubMed/NCBI
13	Hu N, Si Y, Yue J, Sun T, Wang X, Jia Z, Gao S, Li Q, Shao Y, Wang J, et al: Anlotinib has good efficacy and low toxicity: A phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. Cancer Biol Med. 18:849–859. 2021. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Wu D, Zhao B, Tian XL, Yao TC, Li F, Liu WF and Shi AP: Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature. World J Clin Cases. 9:919–926. 2021. View Article : Google Scholar : PubMed/NCBI
15	Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park JM, Spanheimer PM, Li Y, Li T and Weigel RJ: Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell. 25:748–761. 2014. View Article : Google Scholar : PubMed/NCBI
16	Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 98:262–272. 2006. View Article : Google Scholar : PubMed/NCBI
17	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
18	Gu C, Zou S, He C, Zhou J, Qu R, Wang Q, Qi J, Zhou M, Yan S and Ye Z: Long non-coding RNA CCAT1 promotes colorectal cancer cell migration, invasiveness and viability by upregulating VEGF via negative modulation of microRNA-218. Exp Ther Med. 19:2543–2550. 2020.PubMed/NCBI
19	Sui C, Liu D, Hu Y and Zhang L: MicroRNA-708-5p affects proliferation and invasion of osteosarcoma cells by targeting URGCP. Exp Ther Med. 17:2235–2241. 2019.PubMed/NCBI
20	Wang Y, Liu M, Chen S and Wu Q: Plantamajoside represses the growth and metastasis of malignant melanoma. Exp Ther Med. 19:2296–2302. 2020.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
23	Plichta JK, Thomas SM, Vernon R, Fayanju OM, Rosenberger LH, Hyslop T, Hwang ES and Greenup RA: Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Res Treat. 180:227–235. 2020. View Article : Google Scholar : PubMed/NCBI
24	Gouri A, Benarba B, Dekaken A, Aoures H and Benharkat S: Prediction of late recurrence and distant metastasis in early-stage breast cancer: Overview of current and emerging biomarkers. Curr Drug Targets. 21:1008–1025. 2020. View Article : Google Scholar : PubMed/NCBI
25	Woolston C: Breast cancer. Nature. 527:S1012015. View Article : Google Scholar : PubMed/NCBI
26	Franke CM, Gu VW, Grimm BG, Cassady VC, White JR, Weigel RJ and Kulak MV: TFAP2C regulates carbonic anhydrase XII in human breast cancer. Oncogene. 39:1290–1301. 2020. View Article : Google Scholar : PubMed/NCBI
27	Woodfield GW, Horan AD, Chen Y and Weigel RJ: TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res. 67:8439–8443. 2007. View Article : Google Scholar : PubMed/NCBI
28	Perkins SM, Bales C, Vladislav T, Althouse S, Miller KD, Sandusky G, Badve S and Nakshatri H: TFAP2C expression in breast cancer: Correlation with overall survival beyond 10 years of initial diagnosis. Breast Cancer Res Treat. 152:519–531. 2015. View Article : Google Scholar : PubMed/NCBI
29	Wu VT, Kiriazov B, Koch KE, Gu VW, Beck AC, Borcherding N, Li T, Addo P, Wehrspan ZJ, Zhang W, et al: A TFAP2C gene signature is predictive of outcome in HER2-positive breast cancer. Mol Cancer Res. 18:46–56. 2020.PubMed/NCBI
30	Spanheimer PM, Woodfield GW, Cyr AR, Kulak MV, White-Baer LS, Bair TB and Weigel RJ: Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor. Ann Surg Oncol. 20:2204–2212. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kulak MV, Cyr AR, Woodfield GW, Bogachek M, Spanheimer PM, Li T, Price DH, Domann FE and Weigel RJ: Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer. Oncogene. 32:4043–4051. 2013. View Article : Google Scholar : PubMed/NCBI